We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inactivation of 5-HT<sub>2C</sub> Receptors Potentiates Consequences of Serotonin Reuptake Blockade.
- Authors
Cremers, Thomas I.F.H.; Giorgetti, Marco; Bosker, Fokko J.; Hogg, Sandra; Arnt, Jørn; Mørk, Arne; Honig, Gerard; Bøgesø, Klaus-Peter; Westerink, Ben H.C.; den Boer, Hans; Wikstrom, Håkan V.; Tecott, Laurence H.
- Abstract
The enhancement of central serotonin system function underlies the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs), which have become the most commonly used class of antidepressant agents. However, many individuals experience depressive episodes that are resistant to SSRI treatment. Homeostatic mechanisms that limit the extent to which SSRIs enhance serotonergic neurotransmission have been implicated in this phenomenon. Here, we report a novel strategy for enhancing the efficacy of SSRIs. Using in vivo microdialysis methods in rats, the nonselective 5-HT2A receptor antagonist ketanserin was observed to produce a robust augmentation of citalopram-, fluoxetine-, and sertraline-induced elevations of hippocampal extracellular serotonin levels. Similar effects were also observed in cortex. The potentiation of SSRI-induced increases in hippocampal serotonin levels was reproduced by the 5- HT2A receptor-selective antagonists SB 242084 and RS 102221, but not by the S-HT2A receptor-selective antagonist MDL 100 907. Although 5-HT2A receptor antagonists augmented the actions of SSRIs, they had no effect on extracellular serotonin levels or tail suspension responses when administered alone. These results were in strong accord with independent findings using a line of 5-HT2A receptor-null mutant mice. Although this mutation did not affect baseline extracellular serotonin levels or tail suspension test (TST) behavior, it enhanced fluoxetine effects on serotonin levels and immobility in the TST. These findings reveal an unanticipated pharmacological action of 5-HT2A receptors that warrants consideration in the development of novel strategies for the treatment of depression.
- Publication
Neuropsychopharmacology, 2004, Vol 29, Issue 10, p1782
- ISSN
0893-133X
- Publication type
Academic Journal
- DOI
10.1038/sj.npp.1300474